Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegylated liposomal doxorubicin + SL-172154
- Development stage
- Phase 1
- Lead developer
- Shattuck Labs
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Pegylated liposomal doxorubicin (PLD) is a formulation of the anthracycline antibiotic and antineoplastic agent doxorubicin, encapsulated in a pegylated liposome to improve pharmacokinetics and reduce toxicity. It works by intercalating DNA, inhibiting topoisomerase II, and generating free radicals that damage cellular components, leading to cell death. PLD is approved for use in ovarian cancer that has recurred after platinum-based chemotherapy[3][4]. SL-172154 is an investigational Agonist Redirected Checkpoint (ARC) fusion protein developed by Shattuck Labs. It simultaneously inhibits the CD47/SIRPα checkpoint interaction—blocking a "don't eat me" signal on tumor cells—and activates the CD40 costimulatory receptor to stimulate anti-tumor immune responses[1][2][5][6]. The combination of PLD with SL-172154 is being studied in clinical trials for patients with advanced cancers such as platinum-resistant ovarian cancer and acute myeloid leukemia (AML), aiming to enhance both direct cytotoxicity against tumor cells and immune-mediated anti-tumor activity[4][5].
- Brand names
- Caelyx (pegylated liposomal doxorubicin)
- Other names
- PLDpegylated liposomal doxorubicindoxorubicin hydrochloride liposome injection
02
Targets
CD40 (Cluster of differentiation 40 receptor)CD47 (Cluster of Differentiation 47)DNA
Beyond the preview
Go deeper on pegylated liposomal doxorubicin + SL-172154.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegylated liposomal doxorubicin + SL-172154.